Nebiphar (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebiphar, is a beta blocker presented as an oral formulation for oral use. It is indicated for the management of hypertension and heart failure in adult patients, where it helps lower blood pressure and improve cardiac function through selective β1‑adrenergic blockade combined with nitric‑oxide‑mediated vasodilation.

GNH USA supplies Nebiphar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable distribution across global markets and compliance with regulatory standards.

Nebivolol is used to treat conditions within the cardiovascular disease family by modulating heart rate and vascular tone. Hypertension: lowers systolic and diastolic blood pressure in adult patients. Heart failure: improves left‑ventricular ejection fraction and reduces symptoms of chronic heart failure. Elderly patients with hypertension: provides effective blood‑pressure control with a favorable tolerability profile.

Nebivolol may be associated with several adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Headache: mild to moderate headache, often transient. - Dizziness: especially on standing or rapid position changes. - Fatigue: general tiredness or lack of energy. - Nausea: occasional upset stomach or feeling of queasiness.

Serious or Rare Side Effects: - Bradycardia: excessively slow heart rate that may require medical attention. - Hypotension: marked drop in blood pressure leading to faintness. - Heart block: atrioventricular conduction disturbances that can be life‑threatening. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate care.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. Monitor blood pressure: adjust therapy based on regular readings. Assess heart rate: avoid use in patients with severe bradycardia. Caution in hepatic impairment: dose may need adjustment in moderate to severe liver disease. Avoid abrupt discontinuation: risk of rebound hypertension or tachycardia. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Combined with other β‑blockers: risk of excessive bradycardia and hypotension. - Concomitant use with calcium‑channel blockers verapamil or diltiazem: may cause severe AV block. - Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance the hypotensive effect, requiring blood‑pressure monitoring. - ACE inhibitors or ARBs: additive blood‑pressure lowering effect; monitor for symptomatic hypotension.